Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid Digestion01:06

Lipid Digestion

Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Long-Term Use of Sodium-Glucose Co-Transporter-2 Inhibitors on Proteinuria and Renal Function in Patients with Type 2 Diabetes Mellitus without Chronic Kidney Disease during the COVID-19 Pandemic.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia·2025
Same author

The Associations between Kidney Function and Sexual Dysfunction among Males and Females with Type 2 Diabetes Mellitus.

Medicina (Kaunas, Lithuania)·2023
Same author

The role of asymmetric dimethylarginine in endothelial dysfunction and abnormal nitric oxide metabolism in systemic sclerosis: results from a pilot study.

Clinical rheumatology·2022
Same author

Renal effects of sodium-glucose co-transporter-2 inhibitors in patients with heart failure with reduced or preserved ejection fraction.

Nefrologia·2022
Same author

Right ventricular performance in patients with heart failure with mildly reduced ejection fraction: the forgotten ventricle.

The international journal of cardiovascular imaging·2022
Same author

Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study.

Medicina (Kaunas, Lithuania)·2022

Related Experiment Video

Updated: Jun 4, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Ezetimibe and low density lipoprotein subfractions: an ongoing debate.

Niki Katsiki, Vasilis G Athyros, Asterios Karagiannis

    Current Medical Research and Opinion
    |February 1, 2011
    PubMed
    Summary

    Small dense low-density lipoprotein (sdLDL) particles are more atherogenic. This editorial reviews lipid-lowering drug effects on sdLDL, finding more research is needed on ezetimibe (EZE) impacts.

    Related Experiment Videos

    Last Updated: Jun 4, 2026

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
    09:15

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

    Published on: November 10, 2017

    Area of Science:

    • Cardiovascular Medicine
    • Lipid Metabolism
    • Pharmacology

    Background:

    • Small dense low-density lipoprotein (sdLDL) is recognized as a more atherogenic LDL subfraction compared to buoyant LDL.
    • Assessing the impact of lipid-lowering therapies on LDL subfractions is clinically relevant for cardiovascular risk management.

    Discussion:

    • This editorial focuses on the effects of ezetimibe (EZE), a cholesterol transport inhibitor, on sdLDL levels.
    • The discussion examines EZE's impact both as monotherapy and in combination with statins.
    • Current evidence regarding EZE's specific effects on sdLDL subfractions is synthesized.

    Key Insights:

    • Ezetimibe (EZE) is a cholesterol transport inhibitor with potential effects on LDL subfractions.
    • The clinical significance of EZE's impact on atherogenic sdLDL requires further investigation.
    • Existing data are insufficient to definitively conclude EZE's role in modifying sdLDL levels.

    Outlook:

    • Further clinical trials are necessary to elucidate the precise effects of ezetimibe on small dense LDL.
    • Understanding EZE's influence on sdLDL may refine therapeutic strategies for atherosclerosis.
    • Future research should aim to provide definitive answers on ezetimibe's efficacy in altering atherogenic LDL profiles.